13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001822947
Total reported value
$113.1M
$113.1M
25 檔
47.7%
According to the latest 13F quarterly dataset, Ally Bridge Group managed an equity portfolio of $113.1M at the end of Q2 2024, spanning 25 distinct U.S. exchange-listed positions.
During Q2 2024, Ally Bridge Group's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 6.96% | -10.82% | EXIT | |
| 2 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 6.92% | — | — | |
| 3 | GERN | Geron CORP | Stock-Other | 6.91% | — | -0.86% | |
| 4 | ✓ | Merus N V | Stock-Other | 6.16% | — | -31.68% | |
| 5 | INSM | Insmed Inc | Stock-Healthcare | 5.15% | — | -48.40% | |
| 6 | LEGN | Legend Biotech Corp-adr | Stock-Other | 5.15% | — | — | |
| 7 | ALMS | Alumis Inc | Stock-Other | 4.90% | -1.07% | — | |
| 8 | 2655787D | Blueprint Medicines CORP | Stock-Other | 4.86% | — | -53.01% | |
| 9 | IRON | Disc Medicine Inc | Stock-Other | 4.47% | — | — | |
| 10 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 4.40% | — | — | |
| 11 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 4.15% | — | -3.60% | |
| 12 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.93% | — | -45.25% | |
| 13 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.78% | -8.54% | EXIT | |
| 14 | KURA | Kura Oncology Inc | Stock-Other | 3.76% | +2.81% | NEW | |
| 15 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 3.60% | — | — | |
| 16 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 3.53% | — | -19.06% | |
| 17 | CGON | Cg Oncology Inc | Stock-Other | 3.29% | — | -45.42% | |
| 18 | JSPR | Jasper Therapeutics Inc | Stock-Other | 2.96% | — | -24.60% | |
| 19 | TRVI | Trevi Therapeutics Inc | Stock-Other | 2.62% | — | — | |
| 20 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.52% | — | — | |
| 21 | CATX | Perspective Therapeutics Inc | Stock-Other | 2.35% | -0.88% | — | |
| 22 | BDTX | Black Diamond Therapeutics I | Stock-Other | 2.32% | — | — | |
| 23 | CNTX | Context Therapeutics Inc | Stock-Other | 2.25% | — | +159.83% | |
| 24 | CLYM | Climb Bio Inc | Stock-Other | 2.12% | +2.87% | NEW | |
| 25 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 0.95% | — | — |
According to official SEC Form 13F filings, Ally Bridge Group reported a total U.S. public equity portfolio value of $113.1M across 25 disclosed positions in Q2 2024.
During Q2 2024, Ally Bridge Group's top holdings by market value included SLNOEUR (7.0%)、SRPT (6.9%)、GERN (6.9%). The largest single position, SLNOEUR, represented 7.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SLNOEUR, SRPT, GERN) accounted for 47.7% of total reported equity market value during Q2 2024.
In Q2 2024, Ally Bridge Group made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.